• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CORCYM CANADA CORP. PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CORCYM CANADA CORP. PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVE Back to Search Results
Model Number PVS25
Device Problem Migration or Expulsion of Device (1395)
Patient Problem Aortic Valve Insufficiency/ Regurgitation (4450)
Event Date 12/01/2022
Event Type  Injury  
Manufacturer Narrative
Tavr was performed.
 
Event Description
The manufacturer was informed that on (b)(6) 2022, a perceval sutureless aortic heart valve size 25 was implanted on a patient to replace a native bicuspid aortic valve.Reportedly, during the procedure, they had a very poor visibility with a pliable graph also obstructing their view and a traditional valve would not have worked, medical professionals believed that perceval was the best choice of valve.On (b)(6) 2022, few days post-surgery the patient's echo showed pvl on two sides.Following a post-op ct the patient was taken to the cath lab where it was confirmed the perceval had migrated and was tilted slightly.As such, a tavr was performed.Patient recovered well and both the perceval and tavr has been working well, and no pvl was noticed.Reportedly, patient was doing well and was discharged.Based on the medical judgement received, this was a difficult case that would have been tricky regardless of which valve was used on the day.The patient has a history of bicuspid native aortic valve with previous ascending aorta replacement approximately 7 years ago prior to avr with perceval.Ar and some as were noted prior to avr, as further reported.The manufacturer was informed that no further information will be provided.
 
Manufacturer Narrative
Updated fields: b4, g3, g6, h2, h6.Since the serial number of the device is unknown and the device remained implanted, no further investigation on the device can be performed at this time.As such, the definitive root cause of the reported event cannot be established.Based on the medical judgment received, ''this was a difficult case that would have been tricky regardless of which valve was used on the day''.As such, the cause of the event can reasonably be traced to the patient condition.Should further information be received in the future, a follow up report will be provided.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PERCEVAL SUTURELESS AORTIC HEART VALVE
Type of Device
TISSUE HEART VALVE
Manufacturer (Section D)
CORCYM CANADA CORP.
5005 north fraser way
burnaby, bc
Manufacturer (Section G)
CORCYM CANADA CORP.
5005 north fraser way
burnaby, bc
Manufacturer Contact
laura mannino
5005 north fraser way
burnaby, bc 
MDR Report Key16661323
MDR Text Key312493498
Report Number3004478276-2023-00131
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P150011
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 06/02/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/03/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberPVS25
Device Catalogue NumberICV1210
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received06/02/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient SexFemale
-
-